Zayoryl-M2 SR Tablet is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 500mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. The sustained-release (SR) formulation ensures a gradual release of active ingredients, promoting stable plasma concentrations and reducing gastrointestinal side effects commonly associated with immediate-release metformin. Zayoryl-M2 SR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes when monotherapy with either agent is inadequate. It is particularly beneficial for patients requiring dual mechanisms of action to achieve optimal blood glucose levels. The combination therapy may reduce the risk of hypoglycemia compared to sulfonylurea monotherapy and supports weight neutrality or modest weight loss due to metformin’s effects. Dosage should be individualized based on patient response and tolerability. Regular monitoring of blood glucose, renal function, and potential adverse effects is recommended during therapy. Zayoryl-M2 SR should be used cautiously in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis.